IL12/23 Blockade with Ustekinumab as a Treatment for Immune-Related Cutaneous Adverse Events

Background: Immune-related cutaneous adverse events (ircAEs) are frequent and may reduce quality of life and consistent dosing. IL12/23 has been implicated in psoriasis, which is reminiscent of the psoriasiform/lichenoid ircAE phenotype. We report the use of ustekinumab as a therapeutic option. Meth...

Descripción completa

Detalles Bibliográficos
Autores principales: Gu, Stephanie L., Maier, Tara, Moy, Andrea P., Dusza, Stephen, Faleck, David M., Shah, Neil J., Lacouture, Mario E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10674871/
https://www.ncbi.nlm.nih.gov/pubmed/38004414
http://dx.doi.org/10.3390/ph16111548

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10674871/
https://www.ncbi.nlm.nih.gov/pubmed/38004414
http://dx.doi.org/10.3390/ph16111548

Ejemplares similares